Home > Press Releases > GLP-1 Obesity Drugs Market

GLP-1 Obesity Drugs Market Likely to Surpass USD 109.8 Billion by 2035

Report Code: HC-35626  |  Published in: Jun 2026, By MarketGenics  |  Number of pages: 333
Get PDF
Buy

Global GLP-1 Obesity Drugs Market Forecast 2035:

According to the report, the global GLP-1 obesity drugs market is likely to grow from USD 13.2 Billion in 2025 to USD 109.8 Billion in 2035 at a highest CAGR of 23.6% during the time period. The increasing awareness of obesity as a chronic metabolic condition is expected to fuel the global GLP-1 obesity drugs market, as people are increasingly looking for long-term weight reduction treatments to bring better cardiometabolic risk management benefits to patients across the patient spectrum. As people are increasingly leaning on treatment options that are effective and patient-friendly, the use of advanced GLP-1 treatments has been further gaining momentum in clinical practice.

Current efforts to develop GLP-1 drugs are centered on increasing the metabolic stability, boosting the efficiency of the receptor, and ensuring consistent therapeutic response in order to maximize long-term outcomes in clinical practice. The progress of these advances is helping to pave the way for wider uptake of GLP-1 medicines in primary and chronic care systems where scalable and effective obesity treatment solutions are needed.

Obesity care integration into structured cardiometabolic disease management programs provides further support for market expansion by facilitating coordinated care strategies across the diabetes and cardiovascular care ecosystem, while also facilitating earlier intervention for the purpose of controlling the long-term progression of disease.

“Key Driver, Restraint, and Growth Opportunity Shaping the Global GLP-1 Obesity Drugs Market

The global GLP-1 obesity drugs market is expanding due to the significant metabolic burden of obesity, the need for long-term obesity management, and a desire for easy access to therapeutic options, as healthcare systems increasingly move toward using more sophisticated GLP-1 drugs to enhance accessibility, adherence, and prolonged treatment success.

Patient adherence, predictable metabolic response and robust clinical monitoring systems are now critical to the success of GLP-1 therapy, and variabilities in treatment response, risk of therapy discontinuation and variable long-term persistence in various patient populations pose therapeutic challenges.

Models of obesity care are evolving and driving market growth, with GLP-1 therapies playing a greater role in preventive and chronic disease management pathways, which allow for earlier intervention in obesity, risk-based treatment approaches and better integration with cardiometabolic health optimization programs.

Expansion of Global GLP-1 Obesity Drugs Market

“Broader Primary Care Adoption, Chronic Disease Reclassification, and Integrated Metabolic Treatment Pathways”

  • As health systems seek long-term metabolic treatment solutions that are scalable and accessible for more patients, GLP-1 obesity medications are being introduced into PHC and OOH settings, beyond specialist clinical settings.
  • The recognition of obesity as a chronic metabolic disease is facilitating the establishment of obesity care pathways, with GLP-1 therapies fitting into well-defined obesity disease management plans together with diabetes and cardiovascular care programs, to help ensure long-term sustainable disease control.
  • The market is also growing with the inclusion of integrated metabolic care pathways, featuring a coordinated approach that integrates pharmaceutical, preventive health and lifestyle care services alongside one another, and across healthcare providers, to deliver improved long-term patient outcomes.

Regional Analysis of Global GLP-1 Obesity Drugs Market

  • North America is dominating the GLP-1 obesity drugs market owing to significant obesity prevalence in the region, the presence of well-established healthcare reimbursement policies and the swift uptake of novel metabolic therapies backed by advanced clinical research networks and robust pharmaceutical infrastructure.
  • The Asia Pacific GLP-1 obesity drugs market is witnessing the fastest growth due to a high prevalence of diabetes and obesity, advanced therapeutics access, high healthcare expenditure, and the adoption of modern drug treatment protocols in emerging healthcare systems.

Prominent players operating in the global GLP-1 Obesity Drugs market AbbVie Inc., Amgen Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, Eli Lilly and Company, Hanmi Pharmaceutical Co., Ltd., Hansoh Pharmaceutical Group, Novo Nordisk A/S, Pfizer Inc. (Metsera), Roche Holding AG, Structure Therapeutics, Inc., YaoPharma Co., Ltd., Other Key Players.

The global GLP-1 Obesity Drugs market has been segmented as follows:

Global GLP-1 Obesity Drugs Market Analysis, by Drug Type

  • GLP-1 Receptor Agonists (GLP-1 RAs)
  • GLP-1/GIP Dual Agonists
  • GLP-1/GIP/Glucagon Triple Agonists (Retatrutide)
  • Oral GLP-1 Agents
  • Injectable GLP-1 Agents

Global GLP-1 Obesity Drugs Market Analysis, by Molecule

  • Semaglutide
  • Liraglutide
  • Tirzepatide
  • Dulaglutide
  • Exenatide
  • Retatrutide
  • Orforglipron
  • Cagrilintide + Semaglutide
  • Mazdutide
  • Other Pipeline Molecules

Global GLP-1 Obesity Drugs Market Analysis, by Route of Administration

  • Injectable
    • Subcutaneous Injection
    • Intravenous Injection
    • Auto-injector Pen
    • Prefilled Syringe
    • Others
  • Oral
    • Oral Tablet
    • Oral Capsule
    • Oral Film / Dissolving Strip

Global GLP-1 Obesity Drugs Market Analysis, by Treatment Indication

  • Obesity (BMI ≥ 30)
  • Overweight with Comorbidities (BMI 27–30)
    • Type 2 Diabetes Mellitus (T2DM)
    • Cardiovascular Disease Risk Reduction
    • Non-Alcoholic Steatohepatitis (NASH / MASH)
    • Obstructive Sleep Apnea
    • Chronic Kidney Disease
    • Polycystic Ovary Syndrome (PCOS)
    • Others
  • Bariatric Surgery Adjunct Therapy

Global GLP-1 Obesity Drugs Market Analysis, by Prescription Type

  • Brand-name / Innovator Drugs
  • Biosimilar GLP-1 Drugs
  • Off-label Prescriptions
  • Generic Small-Molecule GLP-1 Agents

Global GLP-1 Obesity Drugs Market Analysis, by Distribution Channel

  • Hospital Pharmacies
  • Specialty Clinics & Obesity Centers
  • Direct-to-Patient (DTP) Programs
  • Others

Global GLP-1 Obesity Drugs Market Analysis, by Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • South America

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact US

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

  • 1. Research Methodology and Assumptions
    • 1.1. Definitions
    • 1.2. Research Design and Approach
    • 1.3. Data Collection Methods
    • 1.4. Base Estimates and Calculations
    • 1.5. Forecasting Models
      • 1.5.1. Key Forecast Factors & Impact Analysis
    • 1.6. Secondary Research
      • 1.6.1. Open Sources
      • 1.6.2. Paid Databases
      • 1.6.3. Associations
    • 1.7. Primary Research
      • 1.7.1. Primary Sources
      • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
  • 2. Executive Summary
    • 2.1. Global GLP-1 Obesity Drugs Market Outlook
      • 2.1.1. GLP-1 Obesity Drugs Market Size (Value - US$ Bn), and Forecasts, 2021-2035
      • 2.1.2. Compounded Annual Growth Rate Analysis
      • 2.1.3. Growth Opportunity Analysis
      • 2.1.4. Segmental Share Analysis
      • 2.1.5. Geographical Share Analysis
    • 2.2. Market Analysis and Facts
    • 2.3. Supply-Demand Analysis
    • 2.4. Competitive Benchmarking
    • 2.5. Go-to- Market Strategy
      • 2.5.1. Customer/ End-use Industry Assessment
      • 2.5.2. Growth Opportunity Data, 2026-2035
        • 2.5.2.1. Regional Data
        • 2.5.2.2. Country Data
        • 2.5.2.3. Segmental Data
      • 2.5.3. Identification of Potential Market Spaces
      • 2.5.4. GAP Analysis
      • 2.5.5. Potential Attractive Price Points
      • 2.5.6. Prevailing Market Risks & Challenges
      • 2.5.7. Preferred Sales & Marketing Strategies
      • 2.5.8. Key Recommendations and Analysis
      • 2.5.9. A Way Forward
  • 3. Industry Data and Premium Insights
    • 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
      • 3.1.1. Healthcare & Pharmaceutical Industry Ecosystem Analysis
      • 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
      • 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
    • 3.2. Supplier Customer Data
    • 3.3. Technology Roadmap and Developments
    • 3.4. Trade Analysis
      • 3.4.1. Import & Export Analysis, 2025
      • 3.4.2. Top Importing Countries
      • 3.4.3. Top Exporting Countries
    • 3.5. Trump Tariff Impact Analysis
      • 3.5.1. Manufacturer
        • 3.5.1.1. Based on the component & Raw material
      • 3.5.2. Supply Chain
      • 3.5.3. End Consumer
    • 3.6. Raw Material Analysis
  • 4. Market Overview
    • 4.1. Market Dynamics
      • 4.1.1. Drivers
        • 4.1.1.1. Rising global prevalence of obesity and related metabolic disorders such as type 2 diabetes
        • 4.1.1.2. Strong clinical efficacy of GLP-1 therapies in weight reduction and cardiometabolic improvement
        • 4.1.1.3. Increasing adoption of long-acting and convenient injectable and oral treatment formulations
      • 4.1.2. Restraints
        • 4.1.2.1. High cost of GLP-1 therapies limiting accessibility in price-sensitive markets
        • 4.1.2.2. Supply chain constraints and manufacturing capacity limitations leading to product shortages
    • 4.2. Key Trend Analysis
    • 4.3. Regulatory Framework
      • 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
      • 4.3.2. Tariffs and Standards
      • 4.3.3. Impact Analysis of Regulations on the Market
    • 4.4. Ecosystem Analysis
    • 4.5. Porter’s Five Forces Analysis
    • 4.6. PESTEL Analysis
    • 4.7. Global GLP-1 Obesity Drugs Market Demand
      • 4.7.1. Historical Market Size – Value (US$ Bn), 2020-2024
      • 4.7.2. Current and Future Market Size – Value (US$ Bn), 2026–2035
        • 4.7.2.1. Y-o-Y Growth Trends
        • 4.7.2.2. Absolute $ Opportunity Assessment
  • 5. Competition Landscape
    • 5.1. Competition structure
      • 5.1.1. Fragmented v/s consolidated
    • 5.2. Company Share Analysis, 2025
      • 5.2.1. Global Company Market Share
      • 5.2.2. By Region
        • 5.2.2.1. North America
        • 5.2.2.2. Europe
        • 5.2.2.3. Asia Pacific
        • 5.2.2.4. Middle East
        • 5.2.2.5. Africa
        • 5.2.2.6. South America
    • 5.3. Product Comparison Matrix
      • 5.3.1. Specifications
      • 5.3.2. Market Positioning
      • 5.3.3. Pricing
  • 6. Global GLP-1 Obesity Drugs Market Analysis, by Drug Type
    • 6.1. Key Segment Analysis
    • 6.2. GLP-1 Obesity Drugs Market Size (Value - US$ Bn), Analysis, and Forecasts, by Drug Type, 2021-2035
      • 6.2.1. GLP-1 Receptor Agonists (GLP-1 RAs)
      • 6.2.2. GLP-1/GIP Dual Agonists
      • 6.2.3. GLP-1/GIP/Glucagon Triple Agonists (Retatrutide)
      • 6.2.4. Oral GLP-1 Agents
      • 6.2.5. Injectable GLP-1 Agents
  • 7. Global GLP-1 Obesity Drugs Market Analysis, by Molecule
    • 7.1. Key Segment Analysis
    • 7.2. GLP-1 Obesity Drugs Market Size (Value - US$ Bn), Analysis, and Forecasts, by Molecule, 2021-2035
      • 7.2.1. Semaglutide
      • 7.2.2. Liraglutide
      • 7.2.3. Tirzepatide
      • 7.2.4. Dulaglutide
      • 7.2.5. Exenatide
      • 7.2.6. Retatrutide
      • 7.2.7. Orforglipron
      • 7.2.8. Cagrilintide + Semaglutide
      • 7.2.9. Mazdutide
      • 7.2.10. Other Pipeline Molecules
  • 8. Global GLP-1 Obesity Drugs Market Analysis, by Route of Administration
    • 8.1. Key Segment Analysis
    • 8.2. GLP-1 Obesity Drugs Market Size (Value - US$ Bn), Analysis, and Forecasts, by Route of Administration, 2021-2035
      • 8.2.1. Injectable
        • 8.2.1.1. Subcutaneous Injection
        • 8.2.1.2. Intravenous Injection
        • 8.2.1.3. Auto-injector Pen
        • 8.2.1.4. Prefilled Syringe
        • 8.2.1.5. Others
      • 8.2.2. Oral
        • 8.2.2.1. Oral Tablet
        • 8.2.2.2. Oral Capsule
        • 8.2.2.3. Oral Film / Dissolving Strip
  • 9. Global GLP-1 Obesity Drugs Market Analysis, by Treatment Indication
    • 9.1. Key Segment Analysis
    • 9.2. GLP-1 Obesity Drugs Market Size (Value - US$ Bn), Analysis, and Forecasts, by Treatment Indication, 2021-2035
      • 9.2.1. Obesity (BMI ≥ 30)
      • 9.2.2. Overweight with Comorbidities (BMI 27–30)
        • 9.2.2.1. Type 2 Diabetes Mellitus (T2DM)
        • 9.2.2.2. Cardiovascular Disease Risk Reduction
        • 9.2.2.3. Non-Alcoholic Steatohepatitis (NASH / MASH)
        • 9.2.2.4. Obstructive Sleep Apnea
        • 9.2.2.5. Chronic Kidney Disease
        • 9.2.2.6. Polycystic Ovary Syndrome (PCOS)
        • 9.2.2.7. Others
      • 9.2.3. Bariatric Surgery Adjunct Therapy
  • 10. Global GLP-1 Obesity Drugs Market Analysis, by Prescription Type
    • 10.1. Key Segment Analysis
    • 10.2. GLP-1 Obesity Drugs Market Size (Value - US$ Bn), Analysis, and Forecasts, by Prescription Type, 2021-2035
      • 10.2.1. Brand-name / Innovator Drugs
      • 10.2.2. Biosimilar GLP-1 Drugs
      • 10.2.3. Off-label Prescriptions
      • 10.2.4. Generic Small-Molecule GLP-1 Agents
  • 11. Global GLP-1 Obesity Drugs Market Analysis, by Distribution Channel
    • 11.1. Key Segment Analysis
    • 11.2. GLP-1 Obesity Drugs Market Size (Value - US$ Bn), Analysis, and Forecasts, by Connectivity, 2021-2035
      • 11.2.1. Hospital Pharmacies
      • 11.2.2. Specialty Clinics & Obesity Centers
      • 11.2.3. Direct-to-Patient (DTP) Programs
      • 11.2.4. Others
  • 12. Global GLP-1 Obesity Drugs Market Analysis and Forecasts, by Region
    • 12.1. Key Findings
    • 12.2. GLP-1 Obesity Drugs Market Size (Value - US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
      • 12.2.1. North America
      • 12.2.2. Europe
      • 12.2.3. Asia Pacific
      • 12.2.4. Middle East
      • 12.2.5. Africa
      • 12.2.6. South America
  • 13. North America GLP-1 Obesity Drugs Market Analysis
    • 13.1. Key Segment Analysis
    • 13.2. Regional Snapshot
    • 13.3. North America GLP-1 Obesity Drugs Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 13.3.1. Drug Type
      • 13.3.2. Molecule
      • 13.3.3. Route of Administration
      • 13.3.4. Treatment Indication
      • 13.3.5. Prescription Type
      • 13.3.6. Distribution Channel
      • 13.3.7. Country
        • 13.3.7.1. USA
        • 13.3.7.2. Canada
        • 13.3.7.3. Mexico
    • 13.4. USA GLP-1 Obesity Drugs Market
      • 13.4.1. Country Segmental Analysis
      • 13.4.2. Drug Type
      • 13.4.3. Molecule
      • 13.4.4. Route of Administration
      • 13.4.5. Treatment Indication
      • 13.4.6. Prescription Type
      • 13.4.7. Distribution Channel
    • 13.5. Canada GLP-1 Obesity Drugs Market
      • 13.5.1. Country Segmental Analysis
      • 13.5.2. Drug Type
      • 13.5.3. Molecule
      • 13.5.4. Route of Administration
      • 13.5.5. Treatment Indication
      • 13.5.6. Prescription Type
      • 13.5.7. Distribution Channel
    • 13.6. Mexico GLP-1 Obesity Drugs Market
      • 13.6.1. Country Segmental Analysis
      • 13.6.2. Drug Type
      • 13.6.3. Molecule
      • 13.6.4. Route of Administration
      • 13.6.5. Treatment Indication
      • 13.6.6. Prescription Type
      • 13.6.7. Distribution Channel
  • 14. Europe GLP-1 Obesity Drugs Market Analysis
    • 14.1. Key Segment Analysis
    • 14.2. Regional Snapshot
    • 14.3. Europe GLP-1 Obesity Drugs Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 14.3.1. Drug Type
      • 14.3.2. Molecule
      • 14.3.3. Route of Administration
      • 14.3.4. Treatment Indication
      • 14.3.5. Prescription Type
      • 14.3.6. Distribution Channel
      • 14.3.7. Country
        • 14.3.7.1. Germany
        • 14.3.7.2. United Kingdom
        • 14.3.7.3. France
        • 14.3.7.4. Italy
        • 14.3.7.5. Spain
        • 14.3.7.6. Netherlands
        • 14.3.7.7. Nordic Countries
        • 14.3.7.8. Poland
        • 14.3.7.9. Russia & CIS
        • 14.3.7.10. Rest of Europe
    • 14.4. Germany GLP-1 Obesity Drugs Market
      • 14.4.1. Country Segmental Analysis
      • 14.4.2. Drug Type
      • 14.4.3. Molecule
      • 14.4.4. Route of Administration
      • 14.4.5. Treatment Indication
      • 14.4.6. Prescription Type
      • 14.4.7. Distribution Channel
    • 14.5. United Kingdom GLP-1 Obesity Drugs Market
      • 14.5.1. Country Segmental Analysis
      • 14.5.2. Drug Type
      • 14.5.3. Molecule
      • 14.5.4. Route of Administration
      • 14.5.5. Treatment Indication
      • 14.5.6. Prescription Type
      • 14.5.7. Distribution Channel
    • 14.6. France GLP-1 Obesity Drugs Market
      • 14.6.1. Country Segmental Analysis
      • 14.6.2. Drug Type
      • 14.6.3. Molecule
      • 14.6.4. Route of Administration
      • 14.6.5. Treatment Indication
      • 14.6.6. Prescription Type
      • 14.6.7. Distribution Channel
    • 14.7. Italy GLP-1 Obesity Drugs Market
      • 14.7.1. Country Segmental Analysis
      • 14.7.2. Drug Type
      • 14.7.3. Molecule
      • 14.7.4. Route of Administration
      • 14.7.5. Treatment Indication
      • 14.7.6. Prescription Type
      • 14.7.7. Distribution Channel
    • 14.8. Spain GLP-1 Obesity Drugs Market
      • 14.8.1. Country Segmental Analysis
      • 14.8.2. Drug Type
      • 14.8.3. Molecule
      • 14.8.4. Route of Administration
      • 14.8.5. Treatment Indication
      • 14.8.6. Prescription Type
      • 14.8.7. Distribution Channel
    • 14.9. Netherlands GLP-1 Obesity Drugs Market
      • 14.9.1. Country Segmental Analysis
      • 14.9.2. Drug Type
      • 14.9.3. Molecule
      • 14.9.4. Route of Administration
      • 14.9.5. Treatment Indication
      • 14.9.6. Prescription Type
      • 14.9.7. Distribution Channel
    • 14.10. Nordic Countries GLP-1 Obesity Drugs Market
      • 14.10.1. Country Segmental Analysis
      • 14.10.2. Drug Type
      • 14.10.3. Molecule
      • 14.10.4. Route of Administration
      • 14.10.5. Treatment Indication
      • 14.10.6. Prescription Type
      • 14.10.7. Distribution Channel
    • 14.11. Poland GLP-1 Obesity Drugs Market
      • 14.11.1. Country Segmental Analysis
      • 14.11.2. Drug Type
      • 14.11.3. Molecule
      • 14.11.4. Route of Administration
      • 14.11.5. Treatment Indication
      • 14.11.6. Prescription Type
      • 14.11.7. Distribution Channel
    • 14.12. Russia & CIS GLP-1 Obesity Drugs Market
      • 14.12.1. Country Segmental Analysis
      • 14.12.2. Drug Type
      • 14.12.3. Molecule
      • 14.12.4. Route of Administration
      • 14.12.5. Treatment Indication
      • 14.12.6. Prescription Type
      • 14.12.7. Distribution Channel
    • 14.13. Rest of Europe GLP-1 Obesity Drugs Market
      • 14.13.1. Country Segmental Analysis
      • 14.13.2. Drug Type
      • 14.13.3. Molecule
      • 14.13.4. Route of Administration
      • 14.13.5. Treatment Indication
      • 14.13.6. Prescription Type
      • 14.13.7. Distribution Channel
  • 15. Asia Pacific GLP-1 Obesity Drugs Market Analysis
    • 15.1. Key Segment Analysis
    • 15.2. Regional Snapshot
    • 15.3. Asia Pacific GLP-1 Obesity Drugs Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 15.3.1. Drug Type
      • 15.3.2. Molecule
      • 15.3.3. Route of Administration
      • 15.3.4. Treatment Indication
      • 15.3.5. Prescription Type
      • 15.3.6. Distribution Channel
      • 15.3.7. Country
        • 15.3.7.1. China
        • 15.3.7.2. India
        • 15.3.7.3. Japan
        • 15.3.7.4. South Korea
        • 15.3.7.5. Australia and New Zealand
        • 15.3.7.6. Indonesia
        • 15.3.7.7. Malaysia
        • 15.3.7.8. Thailand
        • 15.3.7.9. Vietnam
        • 15.3.7.10. Rest of Asia Pacific
    • 15.4. China GLP-1 Obesity Drugs Market
      • 15.4.1. Country Segmental Analysis
      • 15.4.2. Drug Type
      • 15.4.3. Molecule
      • 15.4.4. Route of Administration
      • 15.4.5. Treatment Indication
      • 15.4.6. Prescription Type
      • 15.4.7. Distribution Channel
    • 15.5. India GLP-1 Obesity Drugs Market
      • 15.5.1. Country Segmental Analysis
      • 15.5.2. Drug Type
      • 15.5.3. Molecule
      • 15.5.4. Route of Administration
      • 15.5.5. Treatment Indication
      • 15.5.6. Prescription Type
      • 15.5.7. Distribution Channel
    • 15.6. Japan GLP-1 Obesity Drugs Market
      • 15.6.1. Country Segmental Analysis
      • 15.6.2. Drug Type
      • 15.6.3. Molecule
      • 15.6.4. Route of Administration
      • 15.6.5. Treatment Indication
      • 15.6.6. Prescription Type
      • 15.6.7. Distribution Channel
    • 15.7. South Korea GLP-1 Obesity Drugs Market
      • 15.7.1. Country Segmental Analysis
      • 15.7.2. Drug Type
      • 15.7.3. Molecule
      • 15.7.4. Route of Administration
      • 15.7.5. Treatment Indication
      • 15.7.6. Prescription Type
      • 15.7.7. Distribution Channel
    • 15.8. Australia and New Zealand GLP-1 Obesity Drugs Market
      • 15.8.1. Country Segmental Analysis
      • 15.8.2. Drug Type
      • 15.8.3. Molecule
      • 15.8.4. Route of Administration
      • 15.8.5. Treatment Indication
      • 15.8.6. Prescription Type
      • 15.8.7. Distribution Channel
    • 15.9. Indonesia GLP-1 Obesity Drugs Market
      • 15.9.1. Country Segmental Analysis
      • 15.9.2. Drug Type
      • 15.9.3. Molecule
      • 15.9.4. Route of Administration
      • 15.9.5. Treatment Indication
      • 15.9.6. Prescription Type
      • 15.9.7. Distribution Channel
    • 15.10. Malaysia GLP-1 Obesity Drugs Market
      • 15.10.1. Country Segmental Analysis
      • 15.10.2. Drug Type
      • 15.10.3. Molecule
      • 15.10.4. Route of Administration
      • 15.10.5. Treatment Indication
      • 15.10.6. Prescription Type
      • 15.10.7. Distribution Channel
    • 15.11. Thailand GLP-1 Obesity Drugs Market
      • 15.11.1. Country Segmental Analysis
      • 15.11.2. Drug Type
      • 15.11.3. Molecule
      • 15.11.4. Route of Administration
      • 15.11.5. Treatment Indication
      • 15.11.6. Prescription Type
      • 15.11.7. Distribution Channel
    • 15.12. Vietnam GLP-1 Obesity Drugs Market
      • 15.12.1. Country Segmental Analysis
      • 15.12.2. Drug Type
      • 15.12.3. Molecule
      • 15.12.4. Route of Administration
      • 15.12.5. Treatment Indication
      • 15.12.6. Prescription Type
      • 15.12.7. Distribution Channel
    • 15.13. Rest of Asia Pacific GLP-1 Obesity Drugs Market
      • 15.13.1. Country Segmental Analysis
      • 15.13.2. Drug Type
      • 15.13.3. Molecule
      • 15.13.4. Route of Administration
      • 15.13.5. Treatment Indication
      • 15.13.6. Prescription Type
      • 15.13.7. Distribution Channel
  • 16. Middle East GLP-1 Obesity Drugs Market Analysis
    • 16.1. Key Segment Analysis
    • 16.2. Regional Snapshot
    • 16.3. Middle East GLP-1 Obesity Drugs Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 16.3.1. Drug Type
      • 16.3.2. Molecule
      • 16.3.3. Route of Administration
      • 16.3.4. Treatment Indication
      • 16.3.5. Prescription Type
      • 16.3.6. Distribution Channel
      • 16.3.7. Country
        • 16.3.7.1. Turkey
        • 16.3.7.2. UAE
        • 16.3.7.3. Saudi Arabia
        • 16.3.7.4. Israel
        • 16.3.7.5. Rest of Middle East
    • 16.4. Turkey GLP-1 Obesity Drugs Market
      • 16.4.1. Country Segmental Analysis
      • 16.4.2. Drug Type
      • 16.4.3. Molecule
      • 16.4.4. Route of Administration
      • 16.4.5. Treatment Indication
      • 16.4.6. Prescription Type
      • 16.4.7. Distribution Channel
    • 16.5. UAE GLP-1 Obesity Drugs Market
      • 16.5.1. Country Segmental Analysis
      • 16.5.2. Drug Type
      • 16.5.3. Molecule
      • 16.5.4. Route of Administration
      • 16.5.5. Treatment Indication
      • 16.5.6. Prescription Type
      • 16.5.7. Distribution Channel
    • 16.6. Saudi Arabia GLP-1 Obesity Drugs Market
      • 16.6.1. Country Segmental Analysis
      • 16.6.2. Drug Type
      • 16.6.3. Molecule
      • 16.6.4. Route of Administration
      • 16.6.5. Treatment Indication
      • 16.6.6. Prescription Type
      • 16.6.7. Distribution Channel
    • 16.7. Israel GLP-1 Obesity Drugs Market
      • 16.7.1. Country Segmental Analysis
      • 16.7.2. Drug Type
      • 16.7.3. Molecule
      • 16.7.4. Route of Administration
      • 16.7.5. Treatment Indication
      • 16.7.6. Prescription Type
      • 16.7.7. Distribution Channel
    • 16.8. Rest of Middle East GLP-1 Obesity Drugs Market
      • 16.8.1. Country Segmental Analysis
      • 16.8.2. Drug Type
      • 16.8.3. Molecule
      • 16.8.4. Route of Administration
      • 16.8.5. Treatment Indication
      • 16.8.6. Prescription Type
      • 16.8.7. Distribution Channel
  • 17. Africa GLP-1 Obesity Drugs Market Analysis
    • 17.1. Key Segment Analysis
    • 17.2. Regional Snapshot
    • 17.3. Africa GLP-1 Obesity Drugs Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 17.3.1. Drug Type
      • 17.3.2. Molecule
      • 17.3.3. Route of Administration
      • 17.3.4. Treatment Indication
      • 17.3.5. Prescription Type
      • 17.3.6. Distribution Channel
      • 17.3.7. Country
        • 17.3.7.1. South Africa
        • 17.3.7.2. Egypt
        • 17.3.7.3. Nigeria
        • 17.3.7.4. Algeria
        • 17.3.7.5. Rest of Africa
    • 17.4. South Africa GLP-1 Obesity Drugs Market
      • 17.4.1. Country Segmental Analysis
      • 17.4.2. Drug Type
      • 17.4.3. Molecule
      • 17.4.4. Route of Administration
      • 17.4.5. Treatment Indication
      • 17.4.6. Prescription Type
      • 17.4.7. Distribution Channel
    • 17.5. Egypt GLP-1 Obesity Drugs Market
      • 17.5.1. Country Segmental Analysis
      • 17.5.2. Drug Type
      • 17.5.3. Molecule
      • 17.5.4. Route of Administration
      • 17.5.5. Treatment Indication
      • 17.5.6. Prescription Type
      • 17.5.7. Distribution Channel
    • 17.6. Nigeria GLP-1 Obesity Drugs Market
      • 17.6.1. Country Segmental Analysis
      • 17.6.2. Drug Type
      • 17.6.3. Molecule
      • 17.6.4. Route of Administration
      • 17.6.5. Treatment Indication
      • 17.6.6. Prescription Type
      • 17.6.7. Distribution Channel
    • 17.7. Algeria GLP-1 Obesity Drugs Market
      • 17.7.1. Country Segmental Analysis
      • 17.7.2. Drug Type
      • 17.7.3. Molecule
      • 17.7.4. Route of Administration
      • 17.7.5. Treatment Indication
      • 17.7.6. Prescription Type
      • 17.7.7. Distribution Channel
    • 17.8. Rest of Africa GLP-1 Obesity Drugs Market
      • 17.8.1. Country Segmental Analysis
      • 17.8.2. Drug Type
      • 17.8.3. Molecule
      • 17.8.4. Route of Administration
      • 17.8.5. Treatment Indication
      • 17.8.6. Prescription Type
      • 17.8.7. Distribution Channel
  • 18. South America GLP-1 Obesity Drugs Market Analysis
    • 18.1. Key Segment Analysis
    • 18.2. Regional Snapshot
    • 18.3. South America GLP-1 Obesity Drugs Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 18.3.1. Drug Type
      • 18.3.2. Molecule
      • 18.3.3. Route of Administration
      • 18.3.4. Treatment Indication
      • 18.3.5. Prescription Type
      • 18.3.6. Distribution Channel
      • 18.3.7. Country
        • 18.3.7.1. Brazil
        • 18.3.7.2. Argentina
        • 18.3.7.3. Rest of South America
    • 18.4. Brazil GLP-1 Obesity Drugs Market
      • 18.4.1. Country Segmental Analysis
      • 18.4.2. Drug Type
      • 18.4.3. Molecule
      • 18.4.4. Route of Administration
      • 18.4.5. Treatment Indication
      • 18.4.6. Prescription Type
      • 18.4.7. Distribution Channel
    • 18.5. Argentina GLP-1 Obesity Drugs Market
      • 18.5.1. Country Segmental Analysis
      • 18.5.2. Drug Type
      • 18.5.3. Molecule
      • 18.5.4. Route of Administration
      • 18.5.5. Treatment Indication
      • 18.5.6. Prescription Type
      • 18.5.7. Distribution Channel
    • 18.6. Rest of South America GLP-1 Obesity Drugs Market
      • 18.6.1. Country Segmental Analysis
      • 18.6.2. Drug Type
      • 18.6.3. Molecule
      • 18.6.4. Route of Administration
      • 18.6.5. Treatment Indication
      • 18.6.6. Prescription Type
      • 18.6.7. Distribution Channel
  • 19. Key Players/ Company Profile
    • 19.1. AbbVie Inc.
      • 19.1.1. Company Details/ Overview
      • 19.1.2. Company Financials
      • 19.1.3. Key Customers and Competitors
      • 19.1.4. Business/ Industry Portfolio
      • 19.1.5. Product Portfolio/ Specification Details
      • 19.1.6. Pricing Data
      • 19.1.7. Strategic Overview
      • 19.1.8. Recent Developments
    • 19.2. Amgen Inc.
    • 19.3. AstraZeneca plc
    • 19.4. Boehringer Ingelheim GmbH
    • 19.5. Eli Lilly and Company
    • 19.6. Hanmi Pharmaceutical Co., Ltd.
    • 19.7. Hansoh Pharmaceutical Group
    • 19.8. Novo Nordisk A/S
    • 19.9. Pfizer Inc. (Metsera)
    • 19.10. Roche Holding AG
    • 19.11. Structure Therapeutics, Inc.
    • 19.12. YaoPharma Co., Ltd.
    • 19.13. Other Key Players

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF
PRICING DETAILS
USD 4150
USD 5950
USD 7750
Related Report  
YOU MAY ALSO LIKE
Algae Protein Market by Source Type, Form, Protein Content, Production Method, Nature, Extraction Technology, Grade, End-Use Industry, and Geography
Alternative Protein Market by Source/Type, Form, Product Type, Processing Technology, Distribution Channel, Protein Content, End-users, and Geography
Astaxanthin Market by Source/Origin, Form, Grade/Purity Level, Concentration Level, Production Technology, End-users, Distribution Channel, Packaging Type, and Geography
Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation